Literature DB >> 16973280

Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia.

Kari Hänninen1, Heikki Katila, Olli Kampman, Sami Anttila, Ari Illi, Riikka Rontu, Kari M Mattila, Jarmo Hietala, Mikko Hurme, Esa Leinonen, Terho Lehtimäki.   

Abstract

The aim of this study was to investigate the relationship between the functional C957T single-nucleotide polymorphism of the dopamine D2 receptor (DRD2) gene and the risk for schizophrenia. We therefore conducted a case-control association study of 188 Finnish schizophrenia patients meeting the DSM-IV criteria and 384 healthy controls. The 5' nuclease assay (TaqMan) was used to determine genotypes. A greater proportion of patients with schizophrenia than healthy controls were C-allele carriers (odds ratio 1.5, 95% confidence interval (CI) 1.0-2.3, P=0.05). Our results are in agreement with an earlier association study suggesting that the C957T C-allele plays a role in the genetic vulnerability for schizophrenia and support the involvement of the DRD2 gene in schizophrenia pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973280     DOI: 10.1016/j.neulet.2006.08.041

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  PharmGKB summary: dopamine receptor D2.

Authors:  Huaiyu Mi; Paul D Thomas; Huijun Z Ring; Ruhong Jiang; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-06       Impact factor: 2.089

2.  Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions.

Authors:  Yunlong Ma; Wenji Yuan; Xianzhong Jiang; Wen-Yan Cui; Ming D Li
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

Review 3.  A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia.

Authors:  Eleanor H Simpson; Christoph Kellendonk; Eric Kandel
Journal:  Neuron       Date:  2010-03-11       Impact factor: 17.173

Review 4.  Modeling cognitive endophenotypes of schizophrenia in mice.

Authors:  Christoph Kellendonk; Eleanor H Simpson; Eric R Kandel
Journal:  Trends Neurosci       Date:  2009-05-04       Impact factor: 13.837

Review 5.  Dopamine genes and schizophrenia: case closed or evidence pending?

Authors:  Michael E Talkowski; Mikhil Bamne; Hader Mansour; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2007-07-14       Impact factor: 9.306

6.  Components of cross-frequency modulation in health and disease.

Authors:  Elena A Allen; Jingyu Liu; Kent A Kiehl; Joel Gelernter; Godfrey D Pearlson; Nora I Perrone-Bizzozero; Vince D Calhoun
Journal:  Front Syst Neurosci       Date:  2011-07-14

7.  Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: a PRISMA compliant meta-analysis.

Authors:  Hairong He; Huanhuan Wu; Lihong Yang; Fan Gao; Yajuan Fan; Junqin Feng; Xiancang Ma
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-09       Impact factor: 2.570

8.  The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum.

Authors:  C T Smith; L C Dang; J W Buckholtz; A M Tetreault; R L Cowan; R M Kessler; D H Zald
Journal:  Transl Psychiatry       Date:  2017-04-11       Impact factor: 6.222

9.  Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach.

Authors:  Sami Anttila; Olli Kampman; Ari Illi; Riikka Rontu; Terho Lehtimäki; Esa Leinonen
Journal:  BMC Psychiatry       Date:  2007-05-23       Impact factor: 3.630

Review 10.  The role of C957T, TaqI and Ser311Cys polymorphisms of the DRD2 gene in schizophrenia: systematic review and meta-analysis.

Authors:  Thelma Beatriz González-Castro; Yazmín Hernández-Díaz; Isela Esther Juárez-Rojop; María Lilia López-Narváez; Carlos Alfonso Tovilla-Zárate; Alma Genis-Mendoza; Mariela Alpuin-Reyes
Journal:  Behav Brain Funct       Date:  2016-11-09       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.